The RATIONALE study: Outcomes of targeted therapy for metastatic melanoma in Russia
Open Access
- 7 September 2026
- journal article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 26-40
Abstract
Introduction. The efficacy of targeted therapy with the combination of dabrafenib and trametinib in patients with metastatic cutaneous melanoma harboring BRAF mutations has been demonstrated in randomized clinical trials (COMBI-d/v, COMBI-i) and confirmed in real-world clinical practice. The present study aimed to evaluate survival outcomes, tolerability, and treatment modification rates, taking into account the characteristics of clinical practice and the patient population in Russia. The findings are important for optimizing therapeutic strategies and improving the quality of healthcare. Aim. To evaluate the efficacy and safety of dabrafenib plus trametinib in Russian patients with metastatic cutaneous melanoma harboring BRAF V600 mutation in a real-world setting. Materials and methods. RATIONALE is a prospective, non-interventional, multicenter study. A total of 283 patients with unresectable stage IIIC-D and IV melanoma were included. Patients aged ≥ 18 years with metastatic cutaneous melanoma initiated dabrafenib plus trametinib no more than 4 weeks prior to enrolment. The follow-up period was 1 year. Results. Elevated LDH levels were observed in 33.3% of patients, metastases in ≥ 3 organs in 26.5%, and CNS involvement in 18.4%. The 1-year progression-free survival rate was 54% (95% CI: 48–61%), and overall survival was 78% (95% CI: 73–83%). The objective response rate reached 58.0%, with a median time to response of 3.2 months. Adverse events were reported in 35.7% of patients (grade ≥ 3: 12.0%); the most common was pyrexia (16.6%; grade ≥ 3: 4.2%). Treatment discontinuation due to adverse events occurred in 4.6% of patients. Conclusion. In real-world clinical practice, BRAF/MEK targeted therapy has demonstrated effectiveness in the Russian patient population, with outcomes consistent with those observed in randomized clinical trials, despite substantial population heterogeneity and the inclusion of patients with unfavorable prognostic factors.Keywords
This publication has 20 references indexed in Scilit:
- Reponse to letter Re: Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter studyEJC Skin Cancer, 2026
- 1682P Outcomes of first-, second- and third-line treatment with all available combinations of BRAF plus MEK inhibitors in advanced melanoma patients: A real-world studyAnnals of Oncology, 2025
- Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF -mutant metastatic melanoma: a real-world propensity score–matched survival analysisJNCI: Journal of the National Cancer Institute, 2025
- Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanomaESMO Real World Data and Digital Oncology, 2024
- Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint InhibitorsThe Oncologist, 2023
- Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionEuropean Journal of Cancer, 2021
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic MelanomaNew England Journal of Medicine, 2019
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibNew England Journal of Medicine, 2015
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in MelanomaNew England Journal of Medicine, 2014
- Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasisBritish Journal of Cancer, 2012